Psychedelic Companies HAVN Life Sciences, MINDCURE Health Reach Manufacturing Milestones
The global supply chain of regulated psilocybin and ibogaine continues to grow as these Canadian companies beef up manufacturing efforts.
Psychedelic Spotlight News
Will MindMed Partner With Johnson & Johnson for 18MC? ( MNMD & J&J In the Speculation Zone)
What’s up Psychedelic Investors? We all know that MindMed (MNMD / MMED) has been talking about eventually finding partners in the pharmaceuticals industry, but who will be that partner? One persistent Reddit theory posits that it will be none other than Johnson & Johnson. Could this just be a rumor? Perhaps. But depending on how you look at it, there is either some evidence for this theory…or some coincidences.
MindMed is a psychedelic medicines/psychedelic therapy company that is attempting to treat addiction, depression, anxiety and more with LSD, psilocybin (magic mushrooms), 18MC, and other psychedelics. But in order to scale up, they may need the expertise and global reach of a company like JNJ.
MindMed stock (MNMD / MMED) has been quiet for a while now, could a partnership with JNJ be exactly what the company needs? Will MindMed stock go up? Is MindMEd a good investment? Only time will tell!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #JNJ #MNMD
Akome Biotech Patents Psychedelic Drug Formulation to Treat Parkinson’s Disease
There is currently no known cure for the disease affecting 10 million people worldwide, but this psychedelics company thinks it has found a “viable candidate” using DMT.
AOC Is Trying (Again) to End ‘Ridiculous’ War on Drugs to Further Psychedelics Research
AOC says she is “undeterred” after her previous effort to change laws drew laughs from congressional colleagues.
Field Trip Uplists to Nasdaq | Cybin to NYSE | Mydecine MDMA Patent: Big Week For Psychedelic Stocks
Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!
On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.
Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.
In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.
Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/
CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/
MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#FieldTripHealth #Cybin #Mydecine
Interview With James Hallifax
In this episode of the Psychedelic Spotlight podcast, we feature James Hallifax, Co-Founder of The Psychedelic Investor.
How a Psilocybin Study on AIDS Survivors Could Solve a Big Problem with Psychedelic Therapy
A group psilocybin study paves the way for increased scalability of novel treatments that typically require a lot of time for both the patient and therapist.
Psychedelic Business Spotlight: July 23, 2021
This week in psychedelic business news: Psychedelics as a treatment for obesity and TBIs, plus another psychedelic company inches toward listing on NYSE American stock exchange.
Cybin Receives Conditional Approval to Trade on NYSE American
And in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging psychedelics-related companies.
PSYCHEDELICS & The Mental Health Crisis In America: Anxiety, Depression And Addiction ALL TIME HIGHS
The mental healthcare crisis is escalating: Are Psychedelic Medicines the Solution? Can psychedelics health North America fight against anxiety, depression and addiction?
It is well known that during these unprecedented times of lockdowns and fear, our society’s mental health has taken a toll. Unfortunately, few realize how dire the situation has become.
In some respects, this pandemic has accelerated other health care crises: such as the addiction and overdose crisis, the depression crisis, and the anxiety crisis.
These crises can be hard to see when the illnesses are often hidden by those that are experiencing them, out of shame.
However, we can’t start talking about solutions to the problem until we see how big the problem is.
Therefore, in this episode, we are going to take a look at:
1. Some of the data regarding addiction, depression, and anxiety levels during the pandemic, and show you how stark this increase has been;
2. We will discuss a novel solution which has a lot of evidence backing it up: using psychedelics like magic mushrooms and LSD to treat these maladies of the mind;
Enjoy the episode!
Timestamps:
0:00 – Intro
1:37 – Increased rates of Anxiety, Depression & Addiction in North America
6:24 – Psychedelic inspired medicines – potential solutions?
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Links:
Rates of addiction since the epidemic began:
https://www.kten.com/story/44309290/continued-increase-in-substance-abuse-after-pandemic
Rates of overdose:
https://www.google.com/url?q=https://www.forbes.com/sites/niallmccarthy/2021/07/16/us-experiences-a-historic-spike-in-overdose-deaths-infographic/?sh5452ed443650&sa=D&source=editors&ust=1626828792173000&usg=AOvVaw3NuNLOX7F8X_pg9Uh0Rnhv
Rates of depression:
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.nature.com/articles/d41586-021-00175-z
Research into psychedelics as potential alternative treatments
Psilocybin: A potential treatment for depression:
https://newatlas.com/health-wellbeing/psilocybin-therapy-major-depression-trial-results-johns-hopkins/
https://www.imperial.ac.uk/news/219413/magic-mushroom-compound-performs-well-antidepressant/
Psilocybin : A potential cure for Smoking:
https://pubmed.ncbi.nlm.nih.gov/27441452/
Ibogaine: A potential cure for addiction:
https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#ANXIETY#DEPRESSION #PsychedelicTherapy
End of content
End of content